Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

1 Year to 18 Years (Child, Adult)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

HIV infection

Age < 18 years old

BW > 25 kg

HIV RNA viral load < 50 copies within 6 months

Written informed consent

Exclusion Criteria:

Active opportunistic infection

Relevant history or current condition, illness that might interfere with drug absorption, distribution, metabolism or excretion.

Use of concomitant medications that may interfere with the pharmacokinetics of lopinavir/ritonavir